0000899243-18-008643.txt : 20180327 0000899243-18-008643.hdr.sgml : 20180327 20180327175814 ACCESSION NUMBER: 0000899243-18-008643 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20180327 FILED AS OF DATE: 20180327 DATE AS OF CHANGE: 20180327 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PARMAR KUSH CENTRAL INDEX KEY: 0001664281 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38433 FILM NUMBER: 18716575 MAIL ADDRESS: STREET 1: C/O AUDENTES THERAPEUTICS, INC. STREET 2: 101 MONTGOMERY ST., SUITE 2650 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Homology Medicines, Inc. CENTRAL INDEX KEY: 0001661998 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473468154 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 45 WIGGINS AVE. CITY: BEDFORD STATE: MA ZIP: 01730 BUSINESS PHONE: 857-305-1825 MAIL ADDRESS: STREET 1: 45 WIGGINS AVE. CITY: BEDFORD STATE: MA ZIP: 01730 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2018-03-27 0 0001661998 Homology Medicines, Inc. FIXX 0001664281 PARMAR KUSH C/O HOMOLOGY MEDICINES, INC. 45 WIGGINS AVENUE BEDFORD MD 01730 1 0 1 0 Common Stock 1330039 I See footnotes Series A Preferred Stock Common Stock 4204502 I See footnotes Series B Preferred Stock Common Stock 1187535 I See footnotes Includes 1,276,838 shares of common stock held by 5AM Ventures IV, L.P. ("Ventures IV") and 53,201 shares of common stock held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering. Includes 4,036,323 and 168,179 shares of Series A Preferred Stock held by Ventures IV and Co-Investors IV, respectively. Includes 1,140,034 and 47,501 shares of Series B Preferred Stock held by Ventures IV and Co-Investors IV, respectively. 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV and Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV and Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of its or their recurring interest therein. The Reporting Person is an affiliate of Partners IV and disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Exhibit 24 - Power of Attorney /s/ Bradford Smith, Attorney-in-Fact for Kush Parmar 2018-03-27 EX-24 2 attachment1.htm EX-24 DOCUMENT

                               POWER OF ATTORNEY

     With respect to holdings of and transactions in securities issued by
Homology Medicines, Inc. (the "Company"), the undersigned hereby constitutes and
appoints the individuals named on Schedule A attached hereto and as may be
amended from time to time, or any of them signing singly, with full power of
substitution and resubstitution, to act as the undersigned's true and lawful
attorney-in-fact to:

     1.  prepare, execute in the undersigned's name and on the undersigned's
         behalf, and submit to the United States Securities and Exchange
         Commission (the "SEC") a Form ID, including amendments thereto, and any
         other documents necessary or appropriate to obtain and/or regenerate
         codes and passwords enabling the undersigned to make electronic filings
         with the SEC of reports required by Section 16(a) of the Securities
         Exchange Act of 1934, as amended, or any rule or regulation of the SEC;

     2.  execute for and on behalf of the undersigned, Forms 3, 4, and 5 in
         accordance with Section 16 of the Securities Exchange Act of 1934, as
         amended, and the rules thereunder;

     3.  do and perform any and all acts for and on behalf of the undersigned
         which may be necessary or desirable to complete and execute any such
         Form 3, 4, or 5, complete and execute any amendment or amendments
         thereto, and timely file such form with the SEC and any stock exchange
         or similar authority; and

     4.  take any other action of any type whatsoever in connection with the
         foregoing which, in the opinion of such attorney-in-fact, may be of
         benefit to, in the best interest of, or legally required by, the
         undersigned, it being understood that the documents executed by such
         attorney-in-fact on behalf of the undersigned pursuant to this Power of
         Attorney shall be in such form and shall contain such terms and
         conditions as such attorney-in-fact may approve in such attorney-in-
         fact's discretion.

     The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution and
resubstitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorneys-in-fact substitute or substitutes, shall
lawfully do or cause to be done by virtue of this Power of Attorney and the
rights and powers herein granted.

     The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Securities Exchange Act of 1934, as amended.

     This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by Homology
Medicines, Inc., unless earlier revoked by the undersigned in a signed writing
delivered to the foregoing attorneys-in-fact.

     IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 11th day of March, 2018.


                                  Signature:     /s/ Kush M. Parmar, Ph.D.
                                                 -------------------------
                                  Print Name:    Kush M. Parmar, Ph.D.


                                  Schedule A

     Individuals Appointed as Attorney-in-Fact with Full Power of Substitution
and Resubstitution:


Arthur Tzianabos, Ph.D.
Bradford Smith
CJ Witalisz